Shares of Neuralstem (CUR), up 11%, stage a rally after the firm announces it received FDA...

|By:, SA News Editor

Shares of Neuralstem (CUR), up 11%, stage a rally after the firm announces it received FDA approval to advance to transplating patients in the upper back region with spinal cord stem cells to treat ALS after previously only injecting in the lower back region.